New hope for tough leukemia? early trial combines three drugs
NCT ID NCT07320235
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new drug called imetelstat, combined with two standard chemotherapy drugs (azacitidine and venetoclax), in adults whose acute myeloid leukemia has returned or not responded to prior treatment. The study has two parts: first, finding a safe dose of imetelstat with azacitidine, then adding venetoclax to see the best dose and early signs of effectiveness. Up to 36 participants will be enrolled at one hospital.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imetelstat (a drug that targets telomerase), azacitidine, and venetoclax
- What this could lead to
- If successful, this could point toward a new treatment option for people with relapsed acute myeloid leukemia who have run out of standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety and dosing. It may not show strong anti-cancer effects, and side effects could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.